More News of Interest

Centers for Medicare and Medicaid Services Grants Transitional Pass-through Payment for the Spine Jack System

"The CMS Transitional Pass-Through payment determination is a monumental step in providing a superior device technology in the treatment of osteoporotic vertebral compression fractures," said Greg Siller, Vice President and General Manager of Stryker's Interventional Spine business.

Philips to Introduce Latest Advancements In Digital Pathology at the European Congress of Pathology 2020 Virtual Event

Building on its strong portfolio to support oncology clinical decision-making, the company brings together the power of imaging, pathology, genomics, and longitudinal data with insights from artificial intelligence, to empower clinicians to deliver clear care pathways with predictable outcomes for every patient.

Zenith Award from American Association for Respiratory Care for Support of Respiratory Therapists Is Awarded to Vapotherm

Award celebrates excellence in support and quality as chosen by AARC member votes

Attune Medical Major Milestones: Including ensoETM in Cardiac Ablation Procedures Published Study and $4 Mil Convertible Note Closing

Dr. Mark Gallagher (St. George’s University Hospital, London UK) evaluated the use of the ensoETM in cardiac ablation procedures to ascertain whether using the esophageal space for temperature management could have the potential to decrease collateral thermal injury related to radio-frequency (RF) ablation for the treatment of atrial fibrillation.

RapidAI Receives FDA Clearance of Rapid LVO For Identification of Suspected Large Vessel Occlusions

RapidAI, the worldwide leader in advanced imaging for stroke, today announced that Rapid LVO has received Food and Drug Administration (FDA) clearance for detecting suspected LVOs (Large Vessel Occlusions).

Rapid LVO helps physicians speed up triage or transfer decision-making. Working in as few as 3 minutes, Rapid LVO uses a vessel tracker in conjunction with assessment of brain regions with reduced blood vessel density to identify suspected LVOs with a sensitivity of 97% and a specificity of 96%. Stroke team members are also immediately notified when a suspected LVO is detected.

“LVOs are the most disabling and deadly ischemic strokes,” said Dr. Greg Albers, Professor of Neurology at Stanford University, Director of the Stanford Stroke Center and cofounder of RapidAI. “The ability to identify LVOs rapidly facilitates more effective treatment. This is why we are very excited about the FDA clearance of Rapid LVO, a significant step forward in stroke diagnostics and care.”

RapidAI makes the most-widely used stroke imaging software for patient care, research, and clinical trials—helping hospitals around the world save time, money, and lives. Rapid® is the only clinically validated platform available and considered by many to be the gold standard for advanced cerebrovascular imaging.

Latest Posts

Centers for Medicare and Medicaid Services Grants Transitional Pass-through Payment for the Spine Jack System

"The CMS Transitional Pass-Through payment determination is a monumental step in providing a superior device technology in the treatment of osteoporotic vertebral compression fractures," said Greg Siller, Vice President and General Manager of Stryker's Interventional Spine business.

Philips to Introduce Latest Advancements In Digital Pathology at the European Congress of Pathology 2020 Virtual Event

Building on its strong portfolio to support oncology clinical decision-making, the company brings together the power of imaging, pathology, genomics, and longitudinal data with insights from artificial intelligence, to empower clinicians to deliver clear care pathways with predictable outcomes for every patient.

Zenith Award from American Association for Respiratory Care for Support of Respiratory Therapists Is Awarded to Vapotherm

Award celebrates excellence in support and quality as chosen by AARC member votes

Fusion Antibodies and Queen’s University Belfast Awarded a £453,000 Grant from Invest Northern Ireland

The two organisations will use the funds to accelerate the discovery of novel therapeutic and diagnostic antibodies with validated anti-infective properties against COVID-19. Building on strong scientific knowhow, a new antibody development platform will be created that will help realise the vision of producing a breakthrough therapeutic that directly targets SARS-CoV-2.

Don't Miss

New England Biolabs® Introduces NEBNext® Custom RNA Depletion Design Tool and RNA Depletion Core Reagent Set for Customizable RNA Depletion

This technology has been superb for eliminating the ribosomal RNA for a range of custom projects, including tracking novel viruses in mosquitoes, longitudinal profiling for astronauts, and host-pathogen interactions in COVID samples.

INTERCEPT Blood System for Cryoprecipitation Receives FDA Approval States Cerus Corporation

"FDA approval of the INTERCEPT Blood System for Cryoprecipitation is an important step forward in our mission to establish pathogen reduction as the standard of care for transfused blood components globally," said William ‘Obi’ Greenman, Cerus’ president and chief executive officer.

Genetron Health Provides Update on HCCscreen™ for Liver Cancer Early Screening in China

Led by the Wuxi municipal government and administered by the National Cancer Center in China, the “Liver Cancer Early Screening Comprehensive Prevention and Control Project” is a public health initiative.

Research Paper Showing ProtoKinetix AAGP® Enhanced Stem Cell Derived Retina Precursor Cells Restoration of Vision

ProtoKinetix notes the research paper has been submitted to a prestigious journal specializing in tissue regeneration for peer review and editing.

OrganaBio to Expand Its cGMP Cell and Gene Therapy Manufacturing Facility: 19,000 Sq. Ft. Slated to Commence Operations In Q3 2021

OrganBio, a Miami-based cGMP facility, will include process development space, ISO 7 cleanrooms, state-of-the-art scientific equipment, analytics and QC laboratories, and a suite of support services to enable OrganaBio and its partners to rapidly and economically self-manufacture clinical materials.